E Boulanger-Scemama1, D Sayag2, T Ha Chau Tran3, M Quaranta-El Maftouhi4, F Rumen5, C Creuzot-Garcher6, R Blanco Garavito1, C Jung7, E Souied8. 1. Service d'ophtalmologie, université Paris Est Créteil, CHI de Créteil, 40, avenue de Verdun, 94000 Créteil, France. 2. Centre Explore Vision, 75001 Paris, France. 3. Service d'ophtalmologie, groupement des hôpitaux catholique de Lille, université catholique de Lille, 59000 Lille, France. 4. Centre ophtalmologique Rabelais, 69003 Lyon, France. 5. Centre Atlantique de la Vision, 17140 La Rochelle, France. 6. Service d'ophtalmologie, CHU de Dijon, 21079 Dijon, France. 7. Centre de recherche clinique, université Paris Est Créteil, CHI de Créteil, 94000 Créteil, France. 8. Service d'ophtalmologie, université Paris Est Créteil, CHI de Créteil, 40, avenue de Verdun, 94000 Créteil, France. Electronic address: eric.souied@chicreteil.fr.
Abstract
PURPOSE: The goal of this study was to evaluate five year functional and anatomical outcomes of wet AMD patients treated with ranibizumab according to a pro re nata (PRN) regimen in real-life practice. METHODS: A retrospective, multicentric chart review of 201 eyes of 201 patients who underwent their first ranibizumab intravitreal injection (IVT) between January 1, 2007 and December 31, 2008 was performed. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on SD-OCT, number of IVT and follow-up visits were collected at baseline and during the entire follow-up period of 5 years. RESULTS: Mean BCVA at baseline was 52.3±16.5 letters. Mean BCVA change from baseline was respectively +2.8, +2.5, +1.8, -0.6 at 1, 2, 3, 4 years of follow-up. At year 5, 43% of eyes had a stable or improved letter score (≥0 letter gain), whereas 29% declined by 15 letters or more, with an overall significant mean decline of 2.8 letters (P<0.05). No correlation was observed between final visual outcome and age, baseline BCVA, type of neovascularization, naive status, number of IVT or number of follow-up visits. On SD-OCT, mean CMT was 293±96μm at baseline and was significantly reduced compared to baseline at each year end-point (P<0.005). The mean number of IVT was 15±10.4 at year 5, with 55% of eyes still being under active treatment. CONCLUSION: PRN ranibizumab in real-life practice improved or stabilized visual acuity over 4 years. During the 5th year, progressive decline of visual acuity was observed.
PURPOSE: The goal of this study was to evaluate five year functional and anatomical outcomes of wet AMDpatients treated with ranibizumab according to a pro re nata (PRN) regimen in real-life practice. METHODS: A retrospective, multicentric chart review of 201 eyes of 201 patients who underwent their first ranibizumab intravitreal injection (IVT) between January 1, 2007 and December 31, 2008 was performed. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on SD-OCT, number of IVT and follow-up visits were collected at baseline and during the entire follow-up period of 5 years. RESULTS: Mean BCVA at baseline was 52.3±16.5 letters. Mean BCVA change from baseline was respectively +2.8, +2.5, +1.8, -0.6 at 1, 2, 3, 4 years of follow-up. At year 5, 43% of eyes had a stable or improved letter score (≥0 letter gain), whereas 29% declined by 15 letters or more, with an overall significant mean decline of 2.8 letters (P<0.05). No correlation was observed between final visual outcome and age, baseline BCVA, type of neovascularization, naive status, number of IVT or number of follow-up visits. On SD-OCT, mean CMT was 293±96μm at baseline and was significantly reduced compared to baseline at each year end-point (P<0.005). The mean number of IVT was 15±10.4 at year 5, with 55% of eyes still being under active treatment. CONCLUSION: PRN ranibizumab in real-life practice improved or stabilized visual acuity over 4 years. During the 5th year, progressive decline of visual acuity was observed.